We are delighted to announce that our latest whitepaper, written in collaboration with Deloitte: 'Australian R&D Cashback and Early Development Activities', is now available to read and download.
This whitepaper explores the Australian government's initiatives designed to help drug developers swiftly advance their products into early-phase clinical trials, while also benefiting from R&D tax incentives. With streamlined processes, cost efficiencies, a simplified regulatory framework, and a high-quality healthcare sector, Australia is a global competitive destination for clinical research.
Media Contact Information:
Scendea - becky.murphy@scendea.com